Sonnet BioTherapeutics Reports Data From Phase 1b/2a Clinical Trial Of SON-080 In Chemotherapy-Induced Peripheral Neuropathy That Support Advancement Into Phase 2 Study
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics reported positive data from its Phase 1b/2a clinical trial of SON-080 for chemotherapy-induced peripheral neuropathy, showing good tolerance and potential symptom improvement. The company plans to seek a partnership for a Phase 2 trial in diabetic peripheral neuropathy.
July 24, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics' positive Phase 1b/2a trial results for SON-080 indicate good tolerance and potential symptom improvement, supporting advancement to a Phase 2 trial. The company seeks a partnership for further trials in diabetic peripheral neuropathy.
The positive trial results and the plan to advance to a Phase 2 trial in a larger indication (diabetic peripheral neuropathy) are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100